Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.

Trends in cancer - 1 Feb 2020

Post Jasmin B, Roodhart Jeanine M L, Snippert Hugo J G

Abstract excerpt

RAS and BRAF proteins are frequently mutated in colorectal cancer (CRC) and have been associated with therapy resistance in metastatic CRC patients. RAS isoforms are considered to act as redundant entities in physiological and pathological settings. However, there is compelling evidence that mutant variants of RAS and BRAF have different oncogenic potentials and therapeutic outcomes. In this review we describe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Culture Techniques
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Organoids

Share to Proto-Oncogene Proteins B-raf

Share to ras Proteins

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 32061302
DOI: 10.1016/j.trecan.2019.12.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.PMID 32061302Read ↗

Cancer modeling in colorectal organoids reveals intrinsic differences between oncogenic <i>RAS</i> and <i>BRAF</i> variantsSemantic proximity Read ↗

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screeningSemantic proximity Read ↗

BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation.Semantic proximity Read ↗

Transcriptomic Analyses and Novel Organoid and Xenograft Modeling Reveals Potential Drug Sensitivities in a KRAS G12V-Mutant Colorectal Cancer Brain MetastasisSemantic proximity Read ↗

Modeling colorectal cancer: A bio‐resource of 50 patient‐derived organoid linesSemantic proximity Read ↗

A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis.Semantic proximity Read ↗

Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis.Semantic proximity Read ↗

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Semantic proximity Read ↗

One Mutation to Rule Them All: Mutant KRAS Controls Tumor Intrinsic and Microenvironment Signaling.Semantic proximity Read ↗

BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data.Semantic proximity Read ↗

Unveiling radiobiological traits and therapeutic responses of BRAFV600E-mutant colorectal cancer via patient-derived organoidsSemantic proximity Read ↗

Generation of Patient-Derived Colorectal Cancer Organoids for RAS Studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.